allogeneic– tag –
-
Hopstem Biotech Closes ~RMB 200M Series C Funding to Accelerate Development of FDA RMAT-Designated iPSC Cell Therapy hNPC01
Insight, China's Pharmaceutical Industry China Overview Hopstem Biotechnology announced the first close of its Series C funding round, raising approximately RMB 200 million (~$40 million USD). This capital will accelerate clinical develo... -
INFORMA Database Analysis Reveals Rapid Growth of Allogeneic NK Cell Immunotherapy, CAR-Engineered NK Cells Transitioning to Standardized Platforms
INFORMA database (journal article) International Overview Natural killer (NK) cell-based immunotherapy is gaining increasing prominence as a cancer treatment strategy due to its inherent cytotoxicity, allogeneic potential, and compatibil... -
AstraZeneca Accelerates Next-Gen Cell Therapy Manufacturing: Gracell’s Rapid Platform Reduces Autologous CAR T Production Time
AstraZeneca UK Overview AstraZeneca is addressing critical challenges in cell therapy by accelerating autologous cell therapy manufacturing and advancing allogeneic and in vivo 'off-the-shelf' approaches. Notably, they are leveraging Gra... -
Liv Hospital Details Advanced ‘Off-the-Shelf’ CAR-T Manufacturing, Promising Scalability and Broader Access
Liv Hospital Turkey Overview Liv Hospital has unveiled its detailed manufacturing process for allogeneic, 'off-the-shelf' CAR-T cell therapy, a significant leap towards overcoming the logistical and cost barriers of current personalized ... -
NueCell Bio Unveils 26,300 Sq Ft Cell Therapy Development Facility in San Diego, Bolstering Clinical & Commercial Manufacturing
PharmaSource USA Overview NueCell Bio has officially opened its 26,300-square-foot cell therapy development facility in San Diego, significantly enhancing its clinical and commercial manufacturing capabilities. The state-of-the-art facil... -
XsellSmart Biopharmaceutical Completes Patient Enrollment in Phase 1 Trial for Universal Cell Therapy XS411 in Parkinson’s-Type Multiple System Atrophy
VCBeat China Overview XsellSmart Biopharmaceutical announced the completion of full participant enrollment in its Phase 1 registrational clinical trial for XS411, a universal cell therapy targeting Parkinson's-type multiple system atroph... -
Rapid Rise of iPSC-Based Therapies: Manufacturing Challenges and FUJIFILM Cellular Dynamics’ Automation Solutions
Contract Pharma International Overview iPSC-based therapies are rapidly advancing as a renewable, standardized source for allogeneic treatments and scalable solutions across various indications. However, manufacturing poses challenges in... -
Capricor Therapeutics Establishes Commercial Manufacturing for Deramiocel Cell Therapy for DMD, Reports Q2 2026 Financials
Capricor Therapeutics USA Overview Capricor Therapeutics reported its Q2 2026 financial results, highlighting commercial and manufacturing readiness for its lead product candidate, Deramiocel. This allogeneic cardiac-derived cell therapy... -
UCSD Advances Next-Gen CAR-T & Gamma Delta T-Cell Therapies for Solid Tumors in Multiple Phase 1 Clinical Trials
UCSD USA Overview UCSD is actively pursuing multiple Phase 1 clinical trials for next-generation cell therapies targeting advanced solid tumors. Featured trials include FT825/ONO-8250, an off-the-shelf HER2 CAR-T, and A2B395, an allogene... -
NueCell Bio Launches 26,300-Square-Foot Cell Therapy Development Facility to Scale CDMO Services in San Diego
PharmaSource USA Overview NueCell Bio has launched as a dedicated cell therapy science and development services company, opening a 26,300-square-foot facility in San Diego to support translational development, process development, analyt...
